Difficult-to-control asthma management through the use of a specific protocol

Clinics

Volumn 65, Issue 9, 2010, Pages 905-918

  Giavina Bianchi, Pedro ^a   Aun, Marcelo Vivolo ^a   Bisaccioni, Carla ^a   Agondi, Rosana ^a   Kalil, Jorge ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Asthma; Difficult to control; Difficult to treat; Management; Protocol; Resistant asthma; Severe asthma

Indexed keywords

ASTHMA; CHRONIC DISEASE; CLINICAL PROTOCOL; GENETICS; HOSPITALIZATION; HUMAN; PHENOTYPE; REVIEW;

ASTHMA; CHRONIC DISEASE; CLINICAL PROTOCOLS; HUMANS; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 78249243895     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010000900014     Document Type: Review

References (175)

1. GINA. The Global Initiative for Asthma. Disponível em: www.ginasthma.com
2. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma - United States, 1980-2004. MMWR Surveill Summ 2007; 56:1-54.
3. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299:1259-60, doi: 10.1136/bmj.299.6710.1259.
4. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007; 62:85-90, doi: 10.1136/thx.2006.066407.
5. Solé D, Yamada E, Vana AT, Costa-Carvalho BT, Naspitz CK. Prevalence of asthma and related symptoms in school-age children in São Paulo, Brazil - International Study of Asthma and Allergies in Children (ISAAC). J Asthma. 1999; 36:205-12, doi: 10.3109/02770909909056318.
6. Solé D, Yamada E, Vana AT, Werneck G, Solano de Freitas L, et al. International study of asthma and allergies in childhood (ISAAC): prevalence of asthma and asthma-related symptoms among Brazilian schoolchildren. J Investig Allergol Clin Immunol. 2001; 11:123-8.
7. Almqvist C, Worm M, Leynaert B, working group of GA2LEN WP 2.5 Gender. Impact of gender on asthma in childhood and adolescence: a GA2LEN review. Allergy. 2008; 63:47-57.
8. ENFUMOSA. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003; 22:470-7, doi: 10.1183/09031936.03.00261903.
9. DATASUS. Disponível em: www.datasus.com
10. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998; 12:1209-18, doi: 10.1183/09031936.98.12051209.
11. Serra-Batlles J, Plaza V, Morejón E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998; 12:1322-6, doi: 10.1183/09031936.98.12061322.
12. American Thoracic Society. Proceedings of the ATS Workshop on Refractory Asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000; 162:2341-51.
13. Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilization. Eur Respir J. 2004; 23:723-9, doi: 10.1183/09031936.04.00004904.
14. Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J. 1999; 13:1198-208.
15. Plaza Moral V, Álvarez Gutiérrez FJ, Casan Clará P, Cobos Barroso N, López Viña A, Llauger Rosselló MA, et al. GEMA. Guía Española para el Manejo del Asma en calidad de Comité Ejecutivo de la GEMA y en representación del grupo de redactores. Arch Bronconeumol. 2003; 39:S1-42, doi: 10.1157/13042409.
16. López-Viña A, Agü ero-Balbín R, Aller-Á lvarez JL, Bazús-González T, Garcia-Cosio FB, Diego-Damiá A, et al. Á rea de Asma-SEPAR. Guidelines for the diagnosis and management of difficult-to-control asthma. Arch Bronconeumol. 2005; 41:513-23.
17. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma, Full Report. 2007.
18. Brito GS, Wang WS, Roque ALF, Castro FFM, Giavina-Bianchi P, Kalil J. Avaliação de Implantação do Prontuário Eletrônico do Ambulató rio da Divisão de Imunologia Clínica e Alergia do ICHC FMUSP. Revista Brasileira de Alergia e Imunopatologia 2004; 27: 163. (Apresentação no XXXI Congresso de Alergia e Imunopatologia; 2004; Belém, Brasil).
19. Consenso Latino-Americano sobre a asma de difícil controle. Drugs of Today. 2006; 42:1-27.
20. Latin-American Consensus on Difficult-to-Control Asthma, 2008. Drugs Today. (Barc). 2008; 44 Suppl 3:1-43.
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardization of spirometry. European Respiratory Journal. 2005; 26:319-38, doi: 10.1183/09031936.05.00034805.
22. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. European Respiratory Journal. 2005; 26:948-68, doi: 10.1183/09031936.05.00035205.
23. Senna G, Passalacqua G, Schiappoli M, Lombardi C, Wilcock L. Correlation among FEV1, nitric oxide and asthma control test in newly diagnosed asthma. Allergy. 2007; 62:207-8, doi: 10.1111/j.1398-9995.2006.01250.x.
24. Rackemann FM. A cinical study of one hundred and fifty cases of bronchial asthma. Arch Intern Med. 1918; XXII:517-52.
25. Leung DYM, Nelson HS, Szefler SJ, Busse WW. Analyzing asthma phenotypes. J Allergy Clin Immunol. 2004; 113:1-2.
26. Miranda C, Busacker A, Baltazar S, Trudeau J, Wenzel S. Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004; 113:101-8, doi: 10.1016/j. jaci.2003.10.041.
27. Platts-Mills TA. Local production of IgG, IgA and IgE antibodies in grass pollen hay fever. The Journal of Immunology. 1979; 122:2218-25.
28. Mosbech H, Dirksen A, Madsen F, Stahl Skov P, Weeke B. House dust mite asthma. Correlation between allergen sensitivity in various organs. Allergy 1987; 42:456-63, doi: 10.1111/j.1398-9995.1987.tb00363.x.
29. Wardaw AJ, Brightling C, Green R, Woltmann G, Pavord I. Eosinophils in asthma and others allergic diseases. Br Med Bull 2000; 56:985-1003, doi: 10.1258/0007142001903490.
30. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999; 160:1532-9.
31. Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis. 1993; 148:713-9.
32. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995; 95:843-52, doi: 10.1016/S0091-6749(95) 70128-1.
33. Lamblin CL, Gosset P, Tillie-Leblond I, Saulnier F, Marquette CH, Wallaert B, et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med. 1998; 157:394-402.
34. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. Current Opinion in Immunology. 1994; 6:838-46, doi: 10.1016/ 0952-7915(94)90002-7.
35. Kourilsky P, Truffa-Bachi P. Cytokine fields and the polarization of the immune response. TRENDS in Immunology. 2001; 22:502-9, doi: 10. 1016/S1471-4906(01)02012-9.
36. Giavina-Bianchi P, Kalil J, Rizzo LV. Development of an animal model for allergic conjunctivitis: influence of genetic factors and allergen concentration on immune response. Acta Ophthalmol. 2008; 86:670-5, doi: 10.1111/j.1600-0420.2007.01134.x.
37. Busse WW, Calhoun WF, Sedgwick JD. Mechanism of airway inflammation in asthma. Am Rev Respir Dis. 1993; 147:S20-4.
38. Santing RE, Olymulder CG, Zaagsma J, Meurs H. Relantionship among allergen-induce early and late phase airway obstructions, bronchial hyperreactivity and inflammation in conscious, unrestrained guinea pigs. J Allergy Clin Immunol. 1994; 93:1021-30, doi: 10.1016/S0091-6749(94)70051-6.
39. Agondi RC, Barros MT, Rizzo LV, Kalil J, Giavina-Bianchi P. Allergic asthma in patients with common variable immunodeficiency. Allergy. 2010; 65:510-5, doi: 10.1111/j.1398-9995.2009.02211.x.
40. Giavina-Bianchi P, Fidalgo S, Duarte AJS. Hipersensibilidade dos pacientes com asma e rinite na cidade de São Paulo. Arch Argent Inmunol Clín. 1996; 27:12. (Apresentação no Congresso Latino Americano de Alergia e Imunologia; 1996; New Orleans, EUA).
41. Ayres JG, Miles JF, Barnes PJ. Brittle asthma. Thorax. 1998; 53:315-21, doi: 10.1136/thx.53.4.315.
42. TENOR Study Group. Borish L, Chips B, Deniz Y, Gujrathi S, Zheng B, Dolan CM. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2005; 95:247-53, doi: 10.1016/S1081-1206(10)61221-5.
43. Damasceno MAS. Morbidade hospitalar por asma: fatores associados à necessidade de internação no Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, entre 1996 e 1998. [dissertação]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 2002.
44. Minshall EM, Leung DYM, Martin RJ, Song YL, Cameron L, Ernst P, et al. Eosinophil associated TGFb1 mRNA expression and airways fibrosis in asthma. Am J Respir Cell Mol Biol. 1997; 17:326-33.
45. Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK. The R576 IL-4 receptor alpha allele correlates with asthma severity. J Allergy Clin Immunol. 1999; 104:1008-14, doi: 10.1016/S0091-6749(99)70082-5.
46. Sandford AJ, Chagani T, Zhu S, Weir TD, Bai TR, Spinelli JJ, et al. Polymorphisms in the IL4, IL4RA and FCERIB genes and asthma severity. J Allergy Clin Immunol. 2000; 106:135-40, doi: 10.1067/mai.2000.107926.
47. Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy. 2004; 34:757-60, doi: 10.1111/j.1365-2222.2004.1938.x.
48. Hall IP. Pharmacogenetics of asthma. Chest. 2006; 130:1873-8, doi: 10. 1378/chest.130.6.1873.
49. Taylor DR. beta-Adrenergic receptor polymorphisms: relationship to the beta-agonist controversy and clinical implications. Expert Opin Pharmacother. 2007; 8:3195-203, doi: 10.1517/14656566.8.18.3195.
50. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomized studies. Lancet. 2007; 370:2118-25, doi: 10.1016/S0140-6736 (07)61906-0.
51. Kim SH, Hur GY, Choi JH, Park HS. Pharmacogenetics of aspirinintolerant asthma. Pharmacogenomics. 2008; 9:85-91, doi: 10.2217/14622416.9.1.85.
52. Morgan WJ, Crain EF, Gruchalla RS, O9Connor GT, Kattan M, Evans R 3rd, et al. Results of a home-based environmental intervention in urban children with asthma. N Engl J Med. 2004; 351:1068-80, doi: 10.1056/ NEJMoa032097.
53. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004; 24:822-33, doi: 10.1183/09031936.04.00039004.
54. Bush RK, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immunol. 2004; 113:227-34, doi: 10.1016/j.jaci.2003.11.023.
55. Hansen NN, Eggleston PA, Krishnan JA, Curtin-Brosnan J, Rand CS, Patino CM, et al. Asthma-related health status determinants of environment control practices for inner-city preschool children. Ann Allergy Asthma Immunol. 2006; 97:409-17, doi: 10.1016/S1081-1206(10) 60809-5.
56. Black PN. Antibiotics for the treatment of asthma. Curr Opin Pharmacol. 2007; 7:266-71, doi: 10.1016/j.coph.2006.11.013.
57. Corrigan CJ. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med. 2002; 1:47-54.
58. Leal OM. Análise de fatores potencialmente agravantes da asma brônquica em pacientes tratados com corticosteró ides sistêmicos [dissertação]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 1998.
59. Singh M, Bara A, Gibson P. Humidity control for chronic asthma. Cochrane Database of Systemic Reviews. 2002; 2:CD003563.
60. Gotzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. Cochrane Database of Systemic Reviews. 2004; 4:CD001187.
61. Naspitz CK, Diniz C, Cândida Rizzo M, Fernández-Caldas E, Sole D. Human scalps as a reservoi of domestic mites. Lancet. 1997; 349:404, doi: 10.1016/S0140-6736(97)80026-8.
62. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004; 24:822-33, doi: 10.1183/09031936.04.00039004.
63. Warman K, Silver EJ, Wood PR. Asthma risk factor assessment: what are the needs of inner-city families? Ann Allergy Asthma Immunol. 2006; 97:S11-5, doi: 10.1016/S1081-1206(10)60779-X.
64. Rabinovitch N, Strand M, Gelfand EW. Particulate levels are associated with early asthma worsening in children with persistent disease. Am J Respir Crit Care Med. 2006; 173:1098-105, doi: 10.1164/rccm. 200509-1393OC.
65. Giavina-Bianchi PF Jr, Castro FF, Machado ML, Duarte AJ. Occupational respiratory allergic disease induced by Passiflora alata and Rhamnus purshiana. Ann Allergy Asthma Immunol. 1997; 79:449-54, doi: 10.1016/S1081-1206(10)63042-6.
66. Bettiol J, Sele J, Henket M, Louis E, Malaise M, Bartsch P, et al. Cytokine production from sputum cells after allergenic challenge in IgEmediated asthma. Allergy. 2002; 57:1145-50, doi: 10.1034/j.1398-9995.2002.23586.x.
67. Wilson DR, Merret TG, Varga EM, Smurthwaite L, Gould HJ, Kemp M, et al. Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. American Journal of Respiratory Critical Care Medicine. 2002; 165:22-6.
68. Melillo G, Bonini S, Cocco G, Davis RJ, De Monchy JGR, Frolund L, et al. EAACI provocation tests with allergens. Report prepared by the European Academy of Allergology and Clinical Immunology Subcommittee on provocation tests with allergens. Allergy. 1997; 52: 1-35.
69. van der Veen MJ, Lopuhaa CE, Aalberse RC, Jansen HM, van der Zee JS. Bronchial allergen challenge with isolated major allergens of Dermatophagoides pteronyssinus: the role of patient characteristics in the early asthmatic response. J Allergy Clin Immunology. 1998; 102:24-31, doi: 10.1016/S0091-6749(98)70051-X.
70. Giavina-Bianchi P, Diniz LC, Agondi RC, Porter MH, Kalil J. Urticaria after specific bronchial challenge. J Allergy Clin Immunol. 2008; 122:214-5, doi: 10.1016/j.jaci.2008.04.004.
71. Hargreave FE, Dolovich J, Boulet LP. Inhalation provocation tests. Semin Respir Med. 1983; 4:224-8, doi: 10.1055/s-2007-1012487.
72. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness: Standardized challenge testing with pharmacological, physical, and sensitizing stimuli in adults. European Respiratory Journal 1993; 6:53-83.
73. Guidelines for Methacholine and Exercise Challenge Testing - 1999. American Journal Respiratory Critical Care Medicine. 2000; 161:309-29.
74. Cochrane GM, Horne R, Chavez P. Compliance in asthma. Eur Respir Rev. 1999; 93:763-9.
75. Smith JR, Mildenhall S, Nobel M, Mugford M, Shepstone L, Harrison BD. Clinician-assessed poor compliance identifies adults with severe asthma who are at risk of adverse outcomes. J Asthma. 2005; 42:437-45.
76. AIRE. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000; 16:802-7, doi: 10.1183/09031936.00.16580200.
77. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol. 2002; 110:58-64, doi: 10.1067/mai.2002.125489.
78. Lai CK, De Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB, et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol. 2003; 111:263-8, doi: 10.1067/mai.2003.1668.
79. Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, Soriano JB, et al. Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005; 17:191-7, doi: 10.1590/S1020-49892005000300007.
80. de Magalhães Simões, dos Santos MA, da Silva Oliveira M, Fontes ES, Fernezlian S, Garippo AL, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy. 2005; 35:602-11, doi: 10.1111/j.1365-2222.2005.02235.x.
81. Vieira JE, Cukier A, Stelmach R, Kasahara DI, Gannam S, Warth M. Comparison of knowledge on asthma: doctors completing internal medicine residency and doctors completing medical school. São Paulo Med J. 2001; 119:101-4.
82. Stelmach R, Robles-Ribeiro PG, Ribeiro M, Oliveira JC, Scalabrini A, Cukier A. Incorrect application technique of metered dose inhalers by internal medicine residents: impact of exposure to a practical situation. J Asthma. 2007; 44:765-8, doi: 10.1080/02770900701645694.
83. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007; 120:S94- S138, doi: 10.1016/j.jaci.2007.09.029.
84. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med. 2004; 170:836-44, doi: 10.1164/rccm.200401-033OC.
85. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129:15-26, doi: 10.1378/chest.129.1.15.
86. Oppenheimer J, Nelson HS. Safety of long-acting beta-agonists in asthma: a review. Curr Opin Pulm Med. 2008; 14:64-9, doi: 10.1097/ MCP.0b013e3282f1980b.
87. Suissa S, Ernst P, Benayoun S, Baltazan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343:332-6, doi: 10.1056/NEJM200008033430504.
88. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995; 98:196-208, doi: 10.1016/S0002-9343 (99)80404-5.
89. Sievert W, Holmes P, King RW. Oesophageal candidosis in patients on high-dose inhaled steroids. Lancet. 1992; 339:1551-2, doi: 10.1016/0140-6736(92)91326-4.
90. Aun MV, Ribeiro MR, Costa Garcia CL, Agondi RC, Kalil J, Giavina-Bianchi P. Esophageal candidiasis--an adverse effect of inhaled corticosteroids therapy. J Asthma. 2009; 46:399-401, doi: 10.1080/02770900902777783.
91. Kanda N, Yasuba H, Takahashi T, Mizuhara Y, Yamazaki S, Imada Y, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol. 2003; 98:2146-8, doi:10.1111/j.1572-0241.2003.07626.x.
92. Kobayashi Y, Yasuba H, Kudou M, Hamada K, Kita H. Esophageal candidiasis as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP). Int J Clin Pharmacol Ther. 2006; 44:193-7.
93. Shuto H, Nagata M, Terashi Y, Yamaguchi M, Takizawa T, Shuto C, Watanabe K, Tosaka K, Okano M, Noguchi H. Esophageal candidiasis as complication of inhaled steroid therapy. Arerugi. 2003; 52: 1053-64.
94. Bisaccioni C, Aun MV, Cajuela E, Kalil J, Agondi RC, Giavina-Bianchi P. Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis. Clinics (Sao Paulo). 2009; 64:769-73.
95. International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy. 1994; 49 (19 Suppl):1-34.
96. ARIA. Allergic rhinitis and its impact on asthma. Bousquet and ARIA Workshop Group. J Allergy Clin Immunol. 2001; 108:S147-333, doi: 10. 1067/mai.2001.118891.
97. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160, doi: 10.1111/j.1398-9995.2007.01620.x.
98. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med. 2000; 162(4 Pt 1):1391-6.
99. O'Connell EJ. The burden of atopy and asthma in children. Allergy. 2004; 59 Suppl 78:7-11, doi: 10.1111/j.1398-9995.2004.00563.x.
100. Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care. 2000; 6:373-8.
101. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004; 20:305-17, doi: 10.1185/030079903125003053.
102. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998; 351:1225-32, doi: 10.1016/S0140-6736(97)07302-9.
103. Upton MN, McConnachie A, McSharry C, Hart CL, Smith GD, Gillis CR, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ. 2000. 8; 321:88-92, doi: 10.1136/bmj.321.7253.88.
104. Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005; 35:728-32, doi: 10.1111/j. 1365-2222.2005.02274.x.
105. Togias A. Rhinitis and asthma: Evidence for respiratory system integration. J Allergy Clin Immunol. 2003; 111:1171-83, doi: 10.1067/ mai.2003.1592.
106. Antonicelli L, Micucci C, Voltolini S, Senna GE, Di Blasi P, Visonà G, et al. Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. Allergy 2007; 62:1064-70, doi: 10.1111/j. 1398-9995.2007.01470.x.
107. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000; 106(5 Suppl):S201-5, doi: 10.1067/mai.2000.110151.
108. Linneberg A, Henrik Nielsen N, Frølund L, Madsen F, Dirksen A, Jørgensen T. Copenhagen Allergy Study. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002; 57:1048-52, doi: 10.1034/j. 1398-9995.2002.23664.x.
109. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002; 109:57-62, doi: 10.1067/mai.2002.120554.
110. Stelmach R, do Patrocínio T Nunes M, Ribeiro M, Cukier A. Effect of treating allergic rhinitis with corticosteroids in patient with mild-tomoderate persistent asthma. Chest. 2005; 128:3140-7, doi: 10.1378/chest.128.5.3140.
111. Agondi RC, Machado ML, Kalil J, Giavina-Bianchi P. Intranasal corticosteroid administration reduces nonspecific bronchial hyperresponsiveness and improves asthma symptoms. J Asthma. 2008; 45:754-7, doi: 10.1080/02770900802249149.
112. Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev. 2003; CD003570.
113. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2003;:CD001496.
114. Nordenstedt H, Nilsson M, Johansson S, Wallander MA, Johnsen R, Hveem K, et al. The relation between gastroesophageal reflux and respiratory symptoms in a population-based study: the Nord- Trondelag health survey. Chest. 2006; 129:1051-6, doi: 10.1378/chest.129.4.1051.
115. Leggett JJ, Johnston BT, Mills M, Gamble J, Heaney LG. Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest. 2005; 127:1227-31, doi: 10.1378/chest.127.4.1227.
116. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirininduced asthma. AIANE Investigators. European Network on Aspirin- Induced Asthma. Eur Respir J. 2000; 16:432-6, doi: 10.1034/j.1399-3003.2000.016003432.x.
117. Awad OG, Fasano MB, Lee JH, Graham SM. Asthma outcomes after endoscopic sinus surgery in aspirin-tolerant versus aspirin-induced asthmatic patients. Am J Rhinol. 2008; 22:197-203, doi: 10.2500/ajr.2008.22.3148.
118. Ceylan E, Gencer M, San I. Nasal polyposis and the severity of asthma. Respirology. 2007; 12:272-6, doi: 10.1111/j.1440-1843.2006.00964.x.
119. Pfaar O, Klimek L. Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol. 2006; 6:161-6.
120. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wöhrl S, Dahlén B, Szczeklik A. Allergy. 2007; 62:1111-8, doi: 10.1111/j.1398-9995.2007.01409.x.
121. Newman KB, Mason UG, Shmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med. 1995; 152:1382-6.
122. Giavina-Bianchi P, Pinto LHE, Sayed S, Cukier A, Kalil J. Development of a specific questionnaire for the suspicion of DPV. In: AAAAI Annual Meeting, 2007, San Diego. J Allergy Clin Immunol. 2007a119:S165.
123. Martin RJ, Blager FB, Gay ML, Wood RP. Paradoxical vocal cord motion in presumed asthmatics. Semin Respir Med. 1987; 8:332-7, doi: 10.1055/ s-2007-1012672.
124. O9Connell MA, Sklarew PR, Goodman DL. Spectrum of presentation of paradoxic vocal cord motion in ambulatory patients. Ann Allergy. 1995; 74:341-4.
125. Christopher KL, Wood RP, Eckert RC, Blager FB, Raney RA, Souhrada JF. Vocal cord dysfunction presenting as asthma. N Engl J Med. 1983; 308:1566-70, doi: 10.1056/NEJM198306303082605.
126. Corren J, Newman KB. Vocal cord dysfunction mimicking bronchial asthma. Postgrad Med. 1992; 92:153-6.
127. Serpa SF. Aspergilose broncopulmonar alérgica: prevalência e critérios diagnósticos em pacientes asmáticos sensíveis ao Aspergillus fumigatus [dissertação]. Rio de Janeiro: Faculdade de Medicina da UFRJ; 1997.
128. Varkey B. Allergic bronchopulmonary aspergillosis: Clinical perspectives. Immunol Allergy Clin North Am. 1998; 18:479-501, doi: 10.1016/ S0889-8561(05)70018-7.
129. Patterson R, Greenberger PA, Randin RC, Roberts M. Allergic bronchopulmonary aspergillosis: Staging as an Aid to Management. Ann Intern Med. 1982; 96:286-91.
130. Rosenberg M, Patterson R, Mintzer R, Cooper JB, Roberts M, Harris KE. Clinical and Immunologic Criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977; 86:405-14.
131. Greenberger PA. Allergic bronchopulmonary aspergillosis. Current Reviews of Allergy and Immunology. J Allergy Clin Immunol. 2002; 5:685-92, doi: 10.1067/mai.2002.130179.
132. Moser M, Crameri R, Brust E, Suter M, Menz G. Clinical aspects of allergic disease: Diagnostic value of recombinant Aspergillus fumigatus allergen I/A for skin testing and serology. J Allergy Clin Immunol. 1993; 93:1-11, doi: 10.1016/0091-6749(94)90227-5.
133. Crameri R. Recombinant Aspergillus fumigatus allergens: From the nucleotide sequences to clinical aplications. Int Arch Allergy Immunol. 1998; 115:99-114, doi: 10.1159/000023889.
134. Almeida MB, Bussamra MH, Rodrigues JC. ABPA diagnosis in cystic fibrosis patients: the clinical utility of IgE specific to recombinant Aspergillus fumigatus allergens. J Pediatr (Rio J). 2006; 82:215-20, doi:10.2223/JPED.1479.
135. de Oliveira E, Giavina-Bianchi P, Fonseca LA, França AT, Kalil J. Allergic bronchopulmonary aspergillosis' diagnosis remains a challenge. Respir Med. 2007; 101:2352-7, doi: 10.1016/j.rmed.2007.06.018.
136. Juçara Zulli Mohovic. Análogos de Asp f 1 (alfa-sarcina, a mitogilina e a restrictocina) no diagnó stico e estadiamento da aspergilose broncopulmonar alérgica [tese]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 2008.
137. Aun MV, Castro-Coelho AP, Montenegro FG, Kalil J, Agondi MV, Giavina-Bianchi P. Hypogammaglobulinemia: Adverse Effect of Systemic Corticosteroid in Severe Asthma Patients. Pôster at AAAAI 66th Annual Meeting; February 26 - March 2, 2010; New Orleans, USA. J Allergy Clin Immunol. 2010; in press.
138. Rosen FS, Eibl M, Roifman C, Fisher A, Volanakis J, Aiuti F, et al. Primary Immunodeficiency Diseases. Clinical and Experimental Immunology. 1999; 118:1-28.
139. Papadopoulou A, Mermiri D, Taousani S, Triga M, Nicolaidou P, Priftis KN. Bronchial hyper-responsiveness in selective IgA deficiency. Pediatr Allergy Immunol. 2005; 16:495-500, doi: 10.1111/j.1399-3038.2005.00316.x.
140. Cunningham-Rundles C. Bodian C. Common Variable Immunodeficiency: Clinical and Immunological Features of 248 Patients. Clinical Immunology. 1999; 92:34-48, doi: 10.1006/clim.1999.4725.
141. Kokron CM, Errante PR, Barros MT, Baracho GV, Camargo MM, Kalil J, et al. Clinical and laboratory aspects of common variable immunodeficiency. Anais da Academia Brasileira de Ciências. 2004; 76:707-26, doi:10.1590/S0001-37652004000400007.
142. Kainulainen L, Varpula M, Liippo K, Svedsrtröm E, Nikoskelainem J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999; 104:1031-6, doi: 10.1016/S0091-6749(99)70085-0.
143. Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. Q J Med. 2002; 95:655-62.
144. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33:1094-100, doi: 10.1002/art.1780330806.
145. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensusconference. Arthritis Rheum. 1994; 37:187-92, doi: 10.1002/art.1780370206.
146. Guillevin L, Pagnoux C, Mouthon L. Churg-Strauss syndrome. Semin Respir Crit Care Med. 2004; 25:535-45, doi: 10.1055/s-2004-836145.
147. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996; 75:17-28, doi: 10.1097/00005792-199601000-00003.
148. Keogh K, Specks U. Churg-Strauss Syndrome. Semin Respir Crit Care Med. 2006; 27:148-57, doi: 10.1055/s-2006-939518.
149. Oh MJ, Lee JY, Kwon NH, Choi DC. Churg-Strauss syndrome: the clinical features and long-term follow-up of 17 patients. J Korean Med Sci. 2006; 21:265-71, doi: 10.3346/jkms.2006.21.2.265.
150. Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum. 1995; 25:28-4, doi: 10.1016/S0049-0172(95)80015-8.
151. Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004; 92:80-7, doi: 10. 1016/S1081-1206(10)61714-0.
152. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol. 2007; 119:1279, doi: 10.1016/j.jaci.2007.01.041.
153. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007; 144:155-8, doi: 10.1159/000103228.
154. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma (correspondence). N Engl J Med. 2006; 355:1281-2, doi: 10.1056/ NEJMc061914.
155. Bargagli E, Rottoli P. Omalizumab treatment associated with Churg- Strauss vasculitis. Int Arch Allergy Immunol. 2007; 145:268, doi: 10.1159/000109296.
156. Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008; 19:364-6, doi: 10.1016/j.ejim.2007.09.001.
157. Giavina-Bianchi P, Agondi R, Kalil J. One year administration of anti- IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol. 2008; 146:176, doi: 10.1159/000113524.
158. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol. 2008; 122:217-8, doi: 10.1016/j.jaci.2008.05.024
159. Giavina-Bianchi P, Giavina-Bianchi M, Agondi RC, Kalil J. Anti-IgE in Churg-Strauss syndrome. Thorax. 2009; 64:272-3.
160. Giavina-Bianchi P, Kalil J. Omalizumab administration in Churg- Strauss syndrome. Eur J Intern Med. 2009; 20:e139, doi: 10.1016/j.ejim.2008.12.008.
161. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churgstrauss syndrome in patients treated with omalizumab. Chest. 2009; 136:507-18, doi: 10.1378/chest.08-2990.
162. Strunk RC, Mascia AV, Lipkowitz MA, Wolf SI. Rehabilitation of a patient with asthma in the outpatient setting. J Allergy Clin Immunol. 1991; 87:601-11, doi: 10.1016/0091-6749(91)90374-W.
163. Ram FSP, Wellington SR, Barnes NC. Inspiratory muscle training for asthma (Cochrane Review). In: The Chochrane Library, Issue 3, 2008. Oxford: Update Software.
164. Calabraro LTYG. O impacto de um programa de reeducação respirató ria em idosos asmáticos [dissertação]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 2008.
165. Carvalho NS, Ribeiro PR, Ribeiro M, Nunes Mdo P, Cukier A, Stelmach R. Comparing asthma and chronic obstructive pulmonary disease in terms of symptoms of anxiety and depression. J Bras Pneumol. 2007; 33:1-6.
166. Chan MTS, Leung DYM, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol 1998; 101:594-601, doi: 10.1016/S0091-6749(98)70165-4.
167. Woolcock AJ. Steroid resistant asthma: what is the clinical definition? Eur Respir J. 1993; 6:743-7.
168. Spahn JD, Leung DYM, Surs W, Harbeck RJ, Nimmagadda S, Szefler SJ. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med. 1995; 151:1709-14.
169. Adcock IM, Lane SJ. Mechanisms of steroid action and resistance in inflammation. Corticosteroid-insensitive asthma: molecular mechanisms. Journal of Endocrinology. 2003; 178:347-55, doi: 10.1677/joe.0.1780347.
170. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999; 160:1001-8.
171. Gibson PG, Simpson J, Saltos N. Heterogeneity of airway inflammation in persistent asthma: Evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001; 19:1329-36, doi: 10.1378/ chest.119.5.1329.
172. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002; 57:643-48, doi: 10. 1136/thorax.57.7.643.
173. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Resp Crit Care Med. 2004; 170:583-93, doi: 10.1164/rccm.200312-1651OC.
174. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60:309-16, doi: 10.1111/j.1398-9995.2004.00772.x.
175. Fahy JV, Fleming HE, Wong HH. The effect of an anti-IgE monoclonal antibody on the early- and late-phase response to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997; 155:1828-34.